BI 409306

Drug Profile

BI 409306

Alternative Names: BI409306; SUB 166499

Latest Information Update: 08 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidementias; Antipsychotics
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Psychotic disorders; Schizophrenia
  • Phase I Cognition disorders

Most Recent Events

  • 22 Jul 2018 Pooled efficacy and adverse events data from two phase II trials in Alzheimer's disease presented at the Alzheimer's Association International Conference 2018 (AAIC-2018)
  • 19 May 2018 Boehringer Ingelheim completes a phase I trial in Alzheimer's disease (In volunteers) in Germany (PO) (IV) (NCT03505151)
  • 27 Apr 2018 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Germany (IV) (NCT03505151)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top